Guardant Health, Inc.

Fundamentals5.0
Price Action7.0
News Sentiment8.0
AI Rating
6.0

Key Drivers

  • Margin strength
  • Cash burn
  • High leverage

AI
AI Summary

6.0

GH is transitioning from a pure validation story to a reimbursement-backed commercialization story, with Shield CRC's guideline support and payer coverage creating the clearest upside path, but the stock now depends on proving durable adoption fast enough to offset heavy cash burn, debt, and execution risk.

Commercialization
ExecutionRisk
FDA‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Margin strength
  • Cash burn
  • High leverage

GH shows strong gross margins and near-term liquidity, but it remains unprofitable, cash-burning, and heavily leveraged, with only modest quarter-over-quarter improvement and a valuation that still depends on future margin expansion.

Liquidity
Unprofitable

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Strong breakout
  • Higher highs
  • Stretched rally

Over the last month, GH broke out sharply from $127 to about $168, holding above the $130-$133 zone with strong higher highs, but the fast advance leaves it stretched and vulnerable to a pullback unless $150 holds.

bullish
caution
Support Level: $150.03, then $143-$137
Resistance Level: $170-$171

Rapid climb from $127.03 to $167.98, peaking at $170.77, signals short-term pullback risk

Sentiment & News

8.0

Key News Insights:

  • Deal Progress
  • FDA Validation
  • Payer Coverage

Gamehost advanced its $13.65/share sale to Pure Casino with shareholder and court approval, while Guardant Health notched FDA validation for Guardant360 CDx and expanded payer coverage for Shield, signaling continued regulatory and commercial momentum. #M&A​

Diagnostics

These updates are incrementally positive for both names, with Gamehost moving closer to closing and Guardant strengthening both its clinical utility and market access